Mitochondrial & Cellular Biology

ATP yield per glucose: glycolysis (2 ATP + 2 NADH), pyruvate dehydrogenase (2 NADH), citric acid cycle (2 ATP + 6 NADH + 2 FADH₂), oxidative phosphorylation (~30-32 ATP from NADH and FADH₂ via ETC + ATP synthase). Total: approximately 30-32 ATP per glucose (earlier estimate of 36-38 was revised based on actual H⁺/ATP ratio). Tissues with highest ATP demand: cardiac muscle (consuming approximately 6kg ATP/day — 15-20× its own weight), skeletal muscle (during exercise), brain (approximately 20% of total body ATP consumption despite 2% body weight), and kidney (active transport of solutes). Barth syndrome cardiomyopathy results from insufficient cardiac ATP production to meet the heart's extraordinary energy demands — cardiac muscle is therefore the most severely affected tissue. Elamipretide's improvement of mitochondrial ATP production is most clinically significant in high-demand tissues.

Cardiolipin (CL) is a unique diphosphatidylglycerol lipid with four fatty acid chains (predominantly linoleic acid in the heart — tetralinoleoyl-CL or CL 18:2₄). CL functions: organising ETC supercomplexes (complexes I+III+IV form a respirasome; CL molecules fill the interfaces between complexes, acting as molecular glue), stabilising cristae curvature (CL's conical shape promotes negative membrane curvature at cristae tips), anchoring cytochrome c to the IMM (CL-cytochrome c interaction is essential for electron transfer), regulating mitophagy (externalised CL on OMM signals damaged mitochondria for degradation), and modulating apoptosis (CL peroxidation → cytochrome c release). In Barth syndrome: TAFAZZIN deficiency → immature CL species (monolysocardiolipin accumulates, mature tetralinoleoyl-CL is deficient) → destabilised cristae → impaired ETC function → reduced ATP, increased ROS → cardiomyopathy, myopathy, neutropenia. Elamipretide binds mature and immature CL species, providing structural stabilisation even with abnormal CL composition.

The cell membrane is a phospholipid bilayer (~5nm thick) with embedded and peripheral proteins (fluid mosaic model, Singer-Nicolson 1972). Lipid composition: phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine (inner leaflet — externalisation signals apoptosis for phagocyte recognition), sphingomyelin, and cholesterol (modulating fluidity). Membrane functions: selective permeability, receptor-mediated signalling (most peptide drug targets — GPCRs, receptor tyrosine kinases — are integral membrane proteins), cell adhesion, and transport. Antimicrobial peptides exploit membrane differences between bacterial and mammalian cells: bacterial membranes have higher anionic phospholipid content (phosphatidylglycerol, cardiolipin) and no cholesterol, providing the electrostatic selectivity that allows cationic AMPs (defensins, LL-37, polymyxins) to preferentially target bacteria while sparing host cells. Daptomycin's calcium-dependent mechanism specifically targets the bacterial membrane through this selectivity.

ETC complexes: Complex I (NADH dehydrogenase, 45 subunits, ~1000kDa — oxidises NADH, pumps 4H⁺), Complex II (succinate dehydrogenase, 4 subunits — oxidises FADH₂, no proton pumping), Complex III (cytochrome bc1, 11 subunits — transfers electrons from CoQ to cytochrome c, pumps 4H⁺ via Q-cycle), Complex IV (cytochrome c oxidase, 13 subunits — transfers electrons to O₂ producing H₂O, pumps 2H⁺), and Complex V (ATP synthase, ~17 subunits — uses proton gradient to synthesise ATP via rotary catalysis, approximately 3H⁺ per ATP). Supercomplex organisation: CI+CIII₂+CIV forms the respirasome, optimising electron transfer and reducing ROS. Cardiolipin fills the supercomplex interfaces. In Barth syndrome, abnormal cardiolipin disrupts supercomplex assembly → electrons leak → superoxide production increases → oxidative damage compounds the ATP deficit. Elamipretide's cardiolipin stabilisation improves supercomplex organisation and reduces electron leak.

Endocytic pathways: clathrin-mediated endocytosis (CME — the primary pathway for receptor internalisation; clathrin triskelia polymerise into coated pits, with cargo selection by adaptor proteins), caveolae-mediated (flask-shaped membrane invaginations enriched in cholesterol and caveolin — involved in some receptor signalling and transcytosis), macropinocytosis (non-specific uptake of large fluid volumes through membrane ruffling — mechanism for some cell-penetrating peptide entry), phagocytosis (specific to professional phagocytes — receptor-mediated ingestion of large particles), and clathrin/caveolae-independent pathways (various mechanisms including flotillin-dependent and GRAF1-dependent). For peptide therapeutics, endocytosis is relevant to: receptor internalisation and signalling (some GPCRs continue to signal from endosomes — endosomal signalling), drug delivery (CPPs and targeted peptide conjugates rely on endocytic uptake), and escape from endosomes (therapeutic cargo must escape into the cytoplasm before lysosomal degradation — the endosomal escape problem).

The ER is responsible for protein folding, quality control, and secretion. ER stress occurs when: unfolded/misfolded protein load exceeds folding capacity (caused by: nutrient deprivation, hypoxia, calcium depletion, viral infection, or proteasome inhibition preventing misfolded protein clearance). The unfolded protein response (UPR) is activated through three sensors: IRE1α (→ XBP1 splicing → ER chaperone upregulation), PERK (→ eIF2α phosphorylation → global translation attenuation + ATF4 activation), and ATF6 (→ cleaved → ER chaperone/ERAD gene transcription). If the UPR fails to restore homeostasis, pro-apoptotic signalling is activated (CHOP transcription factor → BCL-2 family modulation → mitochondrial apoptosis pathway). Proteasome inhibitors (bortezomib, carfilzomib) exploit this: myeloma cells' massive immunoglobulin production generates extreme ER protein folding demand; blocking proteasomal clearance of misfolded proteins overwhelms the UPR → terminal ER stress → apoptosis. Normal cells tolerate proteasome inhibition better because of lower protein synthesis rates.

Regulated exocytosis: stimulus-dependent secretion from specialised cells. In the context of peptide therapeutics: GLP-1R activation on pancreatic beta cells → cAMP/PKA and Epac2 pathways → potentiation of glucose-stimulated insulin granule exocytosis (the molecular basis of GLP-1 RA glucose-dependent insulin secretion); GHRH receptor activation on pituitary somatotrophs → cAMP/PKA → GH granule exocytosis; GnRH receptor activation on gonadotrophs → IP3/calcium → LH/FSH granule exocytosis (pulsatile GnRH drives this; continuous GnRH ultimately depletes granule stores contributing to downregulation). Molecular machinery: SNARE complex (v-SNARE on vesicle/VAMP + t-SNAREs on target membrane/syntaxin + SNAP-25) drives membrane fusion; calcium sensor synaptotagmin triggers fusion in response to calcium influx. Understanding the exocytic machinery contextualises how peptide drugs stimulate hormone release — they amplify or modulate the natural secretory process rather than directly causing non-physiological hormone release.

Mitochondria are double-membrane organelles (1-10μm, hundreds to thousands per cell depending on energy demand) with their own circular DNA (mtDNA, 16,569bp encoding 13 ETC subunits, 22 tRNAs, 2 rRNAs) inherited maternally. The inner membrane is extensively folded into cristae, creating a large surface area for ETC complexes. Mitochondrial functions beyond ATP production: calcium buffering, apoptosis regulation (cytochrome c release triggers caspase cascade), ROS signalling, haem synthesis, steroid synthesis, and ketogenesis. Mitochondrial dysfunction is implicated in: ageing (mitochondrial theory of ageing — accumulated mtDNA mutations + oxidative damage), neurodegenerative diseases, metabolic diseases, cardiomyopathy, and rare mitochondrial diseases like Barth syndrome. Elamipretide targets the inner mitochondrial membrane specifically, representing a novel therapeutic approach to mitochondrial dysfunction distinct from antioxidant supplementation (which has shown limited clinical benefit in most trials).

Mitochondrial dysfunction spectrum: primary mitochondrial diseases (genetic defects in mtDNA or nuclear genes encoding mitochondrial proteins — over 300 causative genes identified; Barth syndrome is one example; others include Leigh syndrome, MELAS, MERRF), and secondary mitochondrial dysfunction (mitochondrial impairment as a consequence of other disease processes — neurodegenerative diseases, diabetes, heart failure, ageing). Diagnostic indicators: elevated lactate (anaerobic glycolysis compensating for impaired oxidative phosphorylation), elevated lactate/pyruvate ratio, respiratory chain enzyme activities (measured in muscle biopsy), mtDNA sequencing, and advanced imaging (MR spectroscopy detecting brain lactate). Elamipretide represents the first approved drug targeting mitochondrial biology via cardiolipin stabilisation. Other mitochondrial therapeutic approaches in development: gene therapy for mtDNA mutations, ETC bypass molecules (idebenone), NAD+ precursors (nicotinamide riboside), and mitochondrial-targeted antioxidants (MitoQ, SkQ1).

Outer mitochondrial membrane (OMM): permeable to small molecules (<5kDa) through VDAC (voltage-dependent anion channel/porin), site of BCL-2 family protein regulation of apoptosis. Intermembrane space: contains cytochrome c (released during apoptosis), pro-apoptotic factors. Inner mitochondrial membrane (IMM): highly impermeable (maintaining proton gradient essential for ATP synthesis), contains ETC complexes (I-IV) and ATP synthase (complex V), and is uniquely enriched in cardiolipin (approximately 20% of IMM lipid content). IMM cristae morphology: cristae junctions regulate metabolite diffusion between intermembrane space and intracristal space, affecting ETC efficiency. Elamipretide mechanism: the peptide's alternating aromatic-cationic structure (D-Arg-Dmt-Lys-Phe-NH2) enables selective accumulation on the IMM (approximately 5000-fold concentration vs cytoplasm), where it binds cardiolipin through electrostatic (cationic residues ↔ anionic cardiolipin headgroups) and hydrophobic (aromatic residues ↔ acyl chains) interactions, stabilising cristae structure and optimising ETC supercomplex assembly.

Mitchell's chemiosmotic hypothesis (Nobel Prize 1978): ETC complexes pump protons from the matrix to the intermembrane space, creating an electrochemical gradient (~180mV membrane potential). ATP synthase harnesses this proton-motive force: protons flow through the Fo subunit (membrane-embedded rotor), driving rotation of the c-ring, which rotates the γ-subunit within the F1 catalytic head (containing three αβ catalytic sites), inducing conformational changes that catalyse ADP + Pi → ATP (binding change mechanism, Boyer — Nobel Prize 1997). Coupling efficiency: normally approximately 40% of the potential energy in the proton gradient is captured as ATP; the remainder is dissipated as heat (contributing to thermogenesis — important for temperature maintenance). Uncoupling proteins (UCP1 in brown adipose tissue) deliberately dissipate the proton gradient as heat (non-shivering thermogenesis). In Barth syndrome, disrupted cristae and supercomplex disassembly reduce coupling efficiency, compounding the ATP deficit with increased heat production and ROS generation.

Aggregation pathways: non-covalent (hydrophobic interactions between exposed surfaces of partially unfolded proteins → soluble oligomers → insoluble amorphous aggregates or ordered amyloid fibrils) and covalent (disulphide bond-mediated crosslinking between oxidised cysteine residues → non-reducible aggregates). In neurodegenerative diseases: amyloid-β aggregates (Alzheimer's), α-synuclein aggregates/Lewy bodies (Parkinson's), tau tangles (Alzheimer's and other tauopathies), huntingtin polyQ aggregates (Huntington's), TDP-43 aggregates (ALS/FTD), and prion protein aggregates (prion diseases). In pharmaceutical manufacturing: peptide aggregation is a major quality concern because aggregated peptides may be: biologically inactive (reduced potency), immunogenic (aggregates can break immune tolerance, triggering anti-drug antibody formation), and difficult to detect by standard HPLC (requiring size-exclusion chromatography, dynamic light scattering, or analytical ultracentrifugation). Formulation strategies to prevent aggregation: optimising pH, adding surfactants (polysorbate 80), controlling temperature, and minimising agitation during processing and storage.

Following agonist binding, GPCRs undergo: (1) desensitisation — GRK phosphorylation of the receptor → beta-arrestin binding → uncoupling from G-proteins (seconds-minutes), (2) internalisation — beta-arrestin recruits clathrin and AP-2 → clathrin-coated pit formation → dynamin-mediated vesicle scission → endosome formation (minutes), (3) intracellular sorting — either recycling to the surface (rapid recycling via Rab4/11 endosomes → receptor resensitisation) or degradation (late endosomes → lysosomes → receptor downregulation). The balance between recycling and degradation determines whether receptor number recovers (resensitisation) or declines (downregulation). For GnRH receptors (which lack cytoplasmic tails), internalisation follows a non-classical pathway — the GnRH receptor does not bind beta-arrestin efficiently, so internalisation is slower and relies on other mechanisms. This unusual receptor biology contributes to the unique pharmacology of GnRH agonist therapy.

The UPS pathway: E1 ubiquitin-activating enzyme (ATP-dependent, 2 human E1s) → E2 ubiquitin-conjugating enzyme (~40 human E2s) → E3 ubiquitin ligase (~600 human E3s — providing substrate specificity) → polyubiquitin chain assembly on target protein (K48-linked chains signal proteasomal degradation) → recognition by 19S proteasome regulatory particle (deubiquitination, unfolding, threading into 20S core) → proteolysis by 20S core particle (three catalytic activities: chymotrypsin-like/β5, trypsin-like/β2, caspase-like/β1). Bortezomib primarily inhibits the β5 chymotrypsin-like activity (IC50 ~0.6 nM, reversible). Carfilzomib also primarily targets β5 but binds irreversibly (epoxyketone warhead). Proteasomal degradation controls: cell cycle (cyclin degradation), transcription (NF-κB activation requires proteasomal IκB degradation), DNA repair, apoptosis regulation, and antigen presentation (proteasome-generated peptides are presented on MHC class I). The UPS handles approximately 80-90% of intracellular protein degradation.